BCR signaling inhibitors differ in their ability to overcome Mcl-1–mediated resistance of CLL B cells to ABT-199Kamil Bojarczuk(Medical University of Warsaw), Dimitar G. Efremov(Macedonian Academy of Sciences and Arts)BloodApril 20, 201610.1182/blood-2015-10-675009Cited by 113SaveCiteExport RISWatch citationsRelated PapersThe Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells|Blood|2007|315Overexpression of the autoimmunity-associated phosphatase PTPN22 promotes survival of antigen-stimulated CLL cells by selectively activating AKT|Blood|2012|79Inhibition of thioredoxin-dependent H2O2 removal sensitizes malignant B-cells to pharmacological ascorbate|Redox Biology|2018|42